RecruitingNCT04503577
Prospective Bladder Cancer Infrastructure (ProBCI)
Prospective Bladder Cancer Infrastructure: an Infrastructure for Observational and Interventional Bladder Cancer Research (ProBCI)
Sponsor
Prospective Bladder Cancer Infrastructure Foundation
Enrollment
3,600 participants
Start Date
Oct 4, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Bladder cancer
- Any stage except Ta
- years or older
- Written informed consent
Exclusion Criteria1
- Note: participation in ProBCI does not exclude the patient from participation in other studies.
Locations(23)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04503577
Related Trials
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT000268841 location
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT0712999379 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Bio Clinical Collection of Urothelial Carcinoma
NCT049704721 location
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT074754031 location